{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T22:59:05Z","timestamp":1752101945152},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13104-017-3095-6","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T08:25:09Z","timestamp":1513671909000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Complete remission of metastatic pheochromocytoma in 123I-metaiodobenzylguanidine scintigraphy after a single session of 131I-metaiodobenzylguanidine therapy: a case report"],"prefix":"10.1186","volume":"10","author":[{"given":"Teruaki","family":"Sugino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Unno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Naiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzo","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Umemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyasu","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Tozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anri","family":"Inaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Kayano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"key":"3095_CR1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1634\/theoncologist.2008-0043","volume":"13","author":"JT Adler","year":"2008","unstructured":"Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, et al. Pheochromocytoma: current approaches and future directions. Oncologist. 2008;13:779\u201393.","journal-title":"Oncologist"},{"key":"3095_CR2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1677\/ERC-07-0074","volume":"14","author":"A Chrisoulidou","year":"2007","unstructured":"Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14:569\u201385.","journal-title":"Endocr Relat Cancer"},{"key":"3095_CR3","doi-asserted-by":"crossref","first-page":"872713","DOI":"10.1155\/2012\/872713","volume":"2012","author":"G Parenti","year":"2012","unstructured":"Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giach\u00e8 V, Mannelli M. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma\/paraganglioma. J Oncol. 2012;2012:872713.","journal-title":"J Oncol"},{"key":"3095_CR4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ncpendmet0396","volume":"3","author":"K Pacak","year":"2007","unstructured":"Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. International symposium on pheochromocytoma. pheochromocytoma: recommendations for clinical practice from the first international symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007;3:92\u2013102.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"3095_CR5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","volume":"96","author":"M Ayala-Ramirez","year":"2011","unstructured":"Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96:717\u201325.","journal-title":"J Clin Endocrinol Metab"},{"key":"3095_CR6","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1530\/EJE-14-0113","volume":"171","author":"E Baudin","year":"2014","unstructured":"Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, et al. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014;171:R111\u201322.","journal-title":"Eur J Endocrinol"},{"key":"3095_CR7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jcem-72-2-455","volume":"72","author":"M Krempf","year":"1991","unstructured":"Krempf M, Lumbroso J, Mornex R, Brendel AJ, Wemeau JL, Delisle MJ, et al. Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 1991;72:455\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"3095_CR8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","volume":"35","author":"GK Gedik","year":"2008","unstructured":"Gedik GK, Hoefnagel CA, Bais E, Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008;35:725\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3095_CR9","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/cncr.23812","volume":"113","author":"H Huang","year":"2008","unstructured":"Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, et al. Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008;113:2020\u20138.","journal-title":"Cancer"},{"key":"3095_CR10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","volume":"4","author":"A Tanabe","year":"2013","unstructured":"Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer. 2013;4:103\u201310.","journal-title":"Horm Cancer"},{"key":"3095_CR11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1507\/endocrj.EJ14-0211","volume":"61","author":"K Yoshinaga","year":"2014","unstructured":"Yoshinaga K, Oriuchi N, Wakabayashi H, Tomiyama Y, Jinguji M, Higuchi T, et al. Drafting committee for guidelines on internal radiotherapy with 131I-MIBG; Japanese Society of Nuclear Medicine in Oncology and Immunology; Japanese Society of Nuclear Medicine. Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. Endocr J. 2014;61:1171\u201380.","journal-title":"Endocr J"},{"key":"3095_CR12","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/apm.12269","volume":"122","author":"R Pai","year":"2014","unstructured":"Pai R, Manipadam MT, Singh P, Ebenazer A, Samuel P, Rajaratnam S. Usefulness of succinate dehydrogenase B (SDHB) immunohistochemistry in guiding mutational screening among patients with pheochromocytoma-paraganglioma syndromes. APMIS. 2014;122:1130\u20135.","journal-title":"APMIS"},{"key":"3095_CR13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12022-011-9189-0","volume":"23","author":"J Favier","year":"2012","unstructured":"Favier J, Igaz P, Burnichon N, Amar L, Lib\u00e9 R, Badoual C, et al. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr Pathol. 2012;23:34\u201342.","journal-title":"Endocr Pathol"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-017-3095-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T21:55:40Z","timestamp":1719698140000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-017-3095-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3095"],"URL":"https:\/\/doi.org\/10.1186\/s13104-017-3095-6","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"750"}}